News Releases
In this section
-
Jun 18, 2003Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
RICHMOND, Va.--(BUSINESS WIRE)--June 18, 2003--Insmed Incorporated (Nasdaq: INSM) announced that data from a study of its proprietary investigational drug, rhIGF-I/rhIGFBP-3, in children with...
-
Jun 17, 2003Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
RICHMOND, Va.--(BUSINESS WIRE)--June 17, 2003--Insmed Incorporated (Nasdaq:INSM) announced today that the Company has been selected to present to the Biotechnology Industry Organization Annual...
-
Jun 12, 2003Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
RICHMOND, Va.--(BUSINESS WIRE)--June 12, 2003--Insmed Incorporated (NasdaqNM: INSM) today announced that positive data from a dose-ranging trial of rhIGF-I/rhIGFBP-3 in adolescent patients with...
-
Jun 2, 2003Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
RICHMOND, Va.--(BUSINESS WIRE)--June 2, 2003--Insmed Incorporated (Nasdaq:INSM) presented data to ASCO from recent studies of the Company's anti-tumor agent, recombinant human insulin-like growth...
-
May 29, 2003Insmed to Present Positive Cancer Data to ASCO
RICHMOND, Va.--(BUSINESS WIRE)--May 29, 2003--Insmed Incorporated (Nasdaq:INSM) reported today that data from recent studies of the Company's anti-tumor agent, recombinant human insulin-like...
-
May 16, 2003Insmed Incorporated to Present at Techvest European Healthcare Conference
RICHMOND, Va.--(BUSINESS WIRE)--May 16, 2003--Insmed Incorporated (Nasdaq: INSM) today announced that Geoffrey Allan, Ph.D., President and CEO of Insmed Incorporated, will present to the Techvest...
-
May 12, 2003Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
GLEN ALLEN, Va., May 12, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq/NMS: INSM), a biopharmaceutical company engaged in the development of drug candidates for the treatment of metabolic...
-
May 2, 2003Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
RICHMOND, Va.--(BUSINESS WIRE)--May 2, 2003-- Highlights: Net loss of ($2.2 million) is $0.2 million lower than prior guidance Average monthly cash burn rate of $740,000 beats stated goal of $1...
-
Apr 25, 2003Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
RICHMOND, Va., Apr 25, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) a leading developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet...
-
Apr 11, 2003Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
RICHMOND, Va., Apr 11, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) announced today that an investment profile, which details the Company's goals for its future financial and...
Contact Us
